Preview

Russian Journal of Child Neurology

Advanced search

USE OF INJECTABLE VALPROATE FORMULATIONS IN STATUS EPILEPTICUS IN ADULTS AND CHILDREN

https://doi.org/10.17650/2073-8803-2014-9-3-23-29

Abstract

One of the most actual problems in emergency neurology is therapy of status epilepticus (SE). Antiepileptic drugs used in therapy of SE must be: 1) simple in usage; 2) have rapid action; 3) have prolonged antiepileptic action; 4) demonstrate minimal side effects on cardiorespiratory system and other vital functions. Unfortunately, such drugs traditional used in therapy of SE as benzodiazepines, phenytoin and barbiturates don’t fulfill all this four qualities. Numerous clinical investigations of last 15 years demonstrated that such drugs are intravenous valproates. Intravenous form of valproate (Convulex) is rational alternative for benzodiazepines in convulsive SE and drug of choice in treatment of symptomatic status in acute brain disturbances and in patients in coma, at non-convulsive forms of SE and in cases of high risk of depression of cardiorespiratory activity. Treatment of SE could be started from high intravenous rapid dose 15 mg / kg given in 5 minutes. 30 minutes later intravenous infusion therapy 1 mg / kg / hour with Convulex should be done. Moderate doses of intravenous Convulex for adults are 20 mg / kg, for adolescents – 25 mg / kg, and for children – 30 mg / kg.

About the Author

A. A. Kholin
Department of Neurology, Neurosurgery, and Medical Genetics, Faculty of Pediatrics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow; Psychoneurology Unit Two, Russian Children’s Clinical Hospital, Ministry of Health of Russia, Moscow
Russian Federation


References

1. Карлов В.А. Пошаговая терапия эпилептического статуса. Общие рекомендации по дозам и схемам введения. М., 2009. С. 3.

2. Карлов В.А., Андреева О.В. Применение инъекционного депакина при лечении эпилептического статуса. Рус мед журн 2001;20(9):889–93.

3. Сидоров А.М. Опыт применения противосудорожного препарата конвулекс на догоспитальном этапе. Материалы Научно-практической конференции «Актуальные вопросы службы скорой помощи». М., 2010.

4. Холин А.А., Воронкова К.В., Пылаева О.А., Петрухин А.С. Эффективность и безопасность внутривенного применения вальпроатов. Журн неврол и психиатр 2010;110(2):1–5.

5. Холин А.А., Ильина Е.С., Лемешко И.Д. и др. Злокачественные мигрирующие парциальные приступы младенчества. Опыт применения инъекционной формы конвулекса при младенческом эпилептическом статусе (наблюдение из практики). Журн неврол и психиатр 2010;110(2):5–12.

6. Agarwal P., Kumar N., Chandra R. еt al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 2007;16(6):527–32.

7. Alldredge B.K. Benzodiazepines for initial treatment of status epilepticus. In: Status еpilepticus: mechanisms and management. C.G. Wasterlain, D.M. Treiman (еds.). London: The MIT Press, 2006. Pр. 525–37.

8. Chang Y.C., Lin J.J., Wang H.S. et al. Intravenous valproate for seizures in 137 Taiwanese children – valproate naive and nonnaive. Acta Neurol Taiwan 2010;19(2):100–6.

9. Chen L., Feng P., Wang J. et al. Intravenous sodium valproate in mainland China for the treatment of diazepam refractory convulsive status epilepticus. J Clin Neurosci 2009;16(4):524–6.

10. DeLorenzo R.J., Hauser W.A., Towne A.R. et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996;46(4): 1029–35.

11. Devinsky O., Leppik I.,Willmore L.J. et аl. Safety of intravenous valproate. Ann Neurol 1995;38(4):670–4.

12. DeWolfe J.L., Knowlton R.C., Beasley M.T. et аl. Hyperammonemia following intravenous valproate loading. Epilepsy Res 2009;85(1):65–71.

13. Gilad R., Izkovitz N., Dabby R. еt аl. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand 2008;118(5): 296–300.

14. Hovinga C.A., Chicella M.F., Rose D.F. еt al. Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. Ann Pharmacother 1999;33(5):579–84.

15. Lapenta L., Morano A., Casciato S. et аl. Clinical experience with intravenous valproate as first-line treatment of status epilepticus and seizure clusters in selected populations. Int J Neurosci 2014;124(1):30–6.

16. Limdi N.A., Knowlton R.K., Cofield S.S. et аl. Safety of rapid intravenous loading of valproate. Epilepsia 2007;48(3):478–83.

17. Limdi N.A., Shimpi A.V., Faught E. et аl. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005;64(2):353–5.

18. Morton L.D., O'Hara K.A., Coots B.P., Pellock J.M. Safety of rapid intravenous valproate infusion in pediatric patients. Pediatr Neurol 2007;36(2):81–3.

19. Naritoku D.K., Mueed S. Intravenous loading of valproate for epilepsy. Clin Neuropharmacol 1999;22(2):102–6.

20. Olsen K.B., Taubøll E., Gjerstad L. Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults. Acta Neurol Scand Suppl 2007;187: 51–4.

21. Peters C.N., Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus – experience in 102 adult patients. Seizure 2005;14(3):164–9.

22. Ramsay R.E., Cantrell D., Collins S.D. et al. Safety and tolerance of rapidly infused Depacon. A randomized trial in subjects with epilepsy. Epilepsy Res 2003;52(3):189–201.

23. Ramsay R.E., Uthman B., Leppik I.E. et al. The tolerability and safety of valproate sodium injection given as an intravenous infusion. J Epilеpsy 1997;10(1):187–93.

24. Tiamkao S., Sawanyawisuth K. Predictorsand prognosis of status epilepticus treated with intravenous sodium valproate. Epileptic Disord 2009;11(3):228–31.

25. Uberall M.A., Trollmann R., Wunsiedler U., Wenzel D. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology 2000;54(11): 2188–9.

26. Van Ness P.C. Pentobarbital and EEG burst suppression in treatment of status epilepticus refractory to benzodiazepines and phenytoin. Epilepsia 1990;31(1): 61–7.

27. Venkataraman V., Wheless J.W. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res 1999;35(2):147–53.

28. Wheless J.W., Vazquez B.R., Kanner A.M. еt аl. Rapid infusion with valproate sodium is well tolerated in patients with epilepsy. Neurology 2004;63(8):1507–8.

29. Wheless J.W., Venkataraman V. Safety of high intravenous valproate loading in epilepsy patients. J Epilepsy 1998;11(6):319–24.

30. Yu K.T., Mills S., Thompson N., Cunanan C. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia 2003;44(5):724–6.


Review

For citations:


Kholin A.A. USE OF INJECTABLE VALPROATE FORMULATIONS IN STATUS EPILEPTICUS IN ADULTS AND CHILDREN. Russian Journal of Child Neurology. 2014;9(3):23-29. (In Russ.) https://doi.org/10.17650/2073-8803-2014-9-3-23-29

Views: 576


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2073-8803 (Print)
ISSN 2412-9178 (Online)